Lung Cancer Trial Results
1. Cetuximab Plus Chemotherapy Extends Survival for Advanced Lung Cancer
(Posted: 06/19/2008) - Patients with advanced non-small-cell lung cancer who received cetuximab (Erbitux) plus chemotherapy lived on average five weeks longer than patients who received chemotherapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
2. Radiotherapy Can Prevent Spread of Small-Cell Lung Cancer to the Brain
(Posted: 06/20/2007, Reviewed: 08/21/2007) - Radiation therapy to the head, given to patients who had responded to chemotherapy for advanced small-cell lung cancer, reduced by about two-thirds the risk that patients' tumors would spread to the brain, according to findings presented at the 2007 ASCO meeting in Chicago.
3. Meta-Analysis Suggests Cisplatin Superior to Carboplatin for Advanced NSCLC
(Posted: 06/19/2007) - Cisplatin is likely a better option than carboplatin for patients with advanced-stage non-small-cell lung cancer (NSCLC), according to a meta-analysis in the June 6, 2007, Journal of the National Cancer Institute.
4. Surgery Does Not Improve Survival for Advanced NSCLC Patients
(Posted: 04/17/2007) - Patients with advanced non-small-cell lung cancer who had surgery following induction chemotherapy did not have better overall or progression-free survival than patients who received radiotherapy following chemotherapy, according to the March 21, 2007, Journal of the National Cancer Institute.
5. Longer Course of Radiation Provides Better Palliation in Advanced NSCLC
(Posted: 01/30/2007) - In patients with advanced non-small cell lung cancer and a poor outlook, a longer, less intense course of radiation treatment improved patients' life expectancy and was cost-effective, according to the Dec. 20, 2006, Journal of the National Cancer Institute.
1 2 3 4 Next >